中国银河给予百奥赛图“谨慎推荐”评级：锚定全球新药发源地，千鼠万抗前景广阔

Group 1 - The core viewpoint of the report is that China Galaxy has given a "cautious recommendation" rating for Baiaosaitu (688796.SH) based on its comprehensive preclinical research and development layout, projecting a profitability inflection point by 2025 [1] - The company is expanding its business model by leveraging gene editing technology, focusing on model animals and preclinical CRO services [1] - The market for humanized antibodies is experiencing high demand, with significant potential for the "thousand mice, ten thousand antibodies" initiative [1]